Overview

Treatment With Oral LY3023414 To Inhibit Homologous Recombination Followed By Prexasertib

Status:
Recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This study evaluates efficacy of LY3023414 followed by prexasertib in patients with metastatic triple negative breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Baylor Research Institute
Collaborator:
Eli Lilly and Company